# PeptideScanner evidence objects: Trofinetide

Every published version of the records placed with Trofinetide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/trofinetide.json. Selected public evidence only; not medical advice.

- Objects: 27
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02715115-trofinetide-v1"></a>

## ClinicalTrials.gov record NCT02715115

> PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide.

- Evidence object: `story:clinicaltrials-gov-nct02715115-trofinetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-08-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02715115-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct02715115-trofinetide-v1
- Content SHA-256: `4764a114315357fbf4b2ffb5b6ea7842fcf2af3c1dfa1ef904503e0fe843550e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02715115 ([`ctg-observation-nct02715115-2020-08-14-575a080ff61c`](#source-ctg-observation-nct02715115-2020-08-14-575a080ff61c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct02715115-2020-08-14-575a080ff61c`](#source-ctg-observation-nct02715115-2020-08-14-575a080ff61c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02715115 at 2026-11-15T21:57:22.404Z. Its registry update date was 2020-08-14, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct02715115-2020-08-14-575a080ff61c`](#source-ctg-observation-nct02715115-2020-08-14-575a080ff61c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02715115-2020-08-14-575a080ff61c`](#source-ctg-observation-nct02715115-2020-08-14-575a080ff61c))

### Sources

<a id="source-ctg-observation-nct02715115-2020-08-14-575a080ff61c"></a>
- **ClinicalTrials.gov record NCT02715115 · retained source version 2020-08-14:575a080ff61c95fce5751935a4e62715a94fbceeef38ed21a742306ab03b8672** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02715115) (`ctg-observation-nct02715115-2020-08-14-575a080ff61c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02715115." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct02715115-trofinetide-v1 SHA-256: 4764a114315357fbf4b2ffb5b6ea7842fcf2af3c1dfa1ef904503e0fe843550e.

---

<a id="clinicaltrials-gov-nct04181723-trofinetide-v1"></a>

## ClinicalTrials.gov record NCT04181723

> PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.

- Evidence object: `story:clinicaltrials-gov-nct04181723-trofinetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04181723-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04181723-trofinetide-v1
- Content SHA-256: `3eee8dda6358bb47fac172c5176e31c6dd5fd480b34c97d8ebde0aed1475742f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04181723 ([`ctg-observation-nct04181723-2024-04-08-f2a2ceab7240`](#source-ctg-observation-nct04181723-2024-04-08-f2a2ceab7240))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct04181723-2024-04-08-f2a2ceab7240`](#source-ctg-observation-nct04181723-2024-04-08-f2a2ceab7240))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct04181723-2024-04-08-f2a2ceab7240`](#source-ctg-observation-nct04181723-2024-04-08-f2a2ceab7240))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04181723-2024-04-08-f2a2ceab7240`](#source-ctg-observation-nct04181723-2024-04-08-f2a2ceab7240))

### Sources

<a id="source-ctg-observation-nct04181723-2024-04-08-f2a2ceab7240"></a>
- **ClinicalTrials.gov record NCT04181723 · retained source version 2024-04-08:f2a2ceab724054f77787c8658b99e54146297a04d8fa34d1473365c4ecc16dfd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04181723) (`ctg-observation-nct04181723-2024-04-08-f2a2ceab7240`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04181723." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04181723-trofinetide-v1 SHA-256: 3eee8dda6358bb47fac172c5176e31c6dd5fd480b34c97d8ebde0aed1475742f.

---

<a id="clinicaltrials-gov-nct04279314-trofinetide-v1"></a>

## ClinicalTrials.gov record NCT04279314

> PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.

- Evidence object: `story:clinicaltrials-gov-nct04279314-trofinetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04279314-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04279314-trofinetide-v1
- Content SHA-256: `d51eeb35c1997e592559463a74e6f14cfd0a47d797ee80b75d55a55321a54af7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04279314 ([`ctg-observation-nct04279314-2024-04-11-0331ca281992`](#source-ctg-observation-nct04279314-2024-04-11-0331ca281992))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct04279314-2024-04-11-0331ca281992`](#source-ctg-observation-nct04279314-2024-04-11-0331ca281992))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide. ([`ctg-observation-nct04279314-2024-04-11-0331ca281992`](#source-ctg-observation-nct04279314-2024-04-11-0331ca281992))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04279314-2024-04-11-0331ca281992`](#source-ctg-observation-nct04279314-2024-04-11-0331ca281992))

### Sources

<a id="source-ctg-observation-nct04279314-2024-04-11-0331ca281992"></a>
- **ClinicalTrials.gov record NCT04279314 · retained source version 2024-04-11:0331ca2819920ba14b0889c926cedeef143b7e06b454764d87e6e8a15b2fc53e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04279314) (`ctg-observation-nct04279314-2024-04-11-0331ca281992`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04279314." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#clinicaltrials-gov-nct04279314-trofinetide-v1 SHA-256: d51eeb35c1997e592559463a74e6f14cfd0a47d797ee80b75d55a55321a54af7.

---

<a id="fda-drugs-nda217026-v1"></a>

## Drugs@FDA application NDA217026

> The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217026:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217026/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda217026-v1
- Content SHA-256: `63e5c833f040625b2857928f63a3c2ac48576de8102ad634a35463e2850c46d1`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217026 ([`fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a`](#source-fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients. ([`fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a`](#source-fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients. ([`fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a`](#source-fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a`](#source-fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a))

### Sources

<a id="source-fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a"></a>
- **Drugs@FDA application NDA217026 · original submission status AP · 2023-03-10 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217026%22&limit=1) (`fda-drugs-nda217026-2023-03-10-4bb0ba3bac8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217026." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda217026-v1 SHA-256: 63e5c833f040625b2857928f63a3c2ac48576de8102ad634a35463e2850c46d1.

---

<a id="fda-drugs-nda219884-v1"></a>

## Drugs@FDA application NDA219884

> The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda219884:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda219884/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda219884-v1
- Content SHA-256: `909dc27392fa1c65e6f2e1e2aa32c29afc65adc0117b6d5c68f1f79eab6c8a22`

### Claims and source pins

#### Headline

Drugs@FDA application NDA219884 ([`fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d`](#source-fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients. ([`fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d`](#source-fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 219884 with status AP dated 2025-12-11, and names trofinetide among the application record's active ingredients. ([`fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d`](#source-fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d`](#source-fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d))

### Sources

<a id="source-fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d"></a>
- **Drugs@FDA application NDA219884 · original submission status AP · 2025-12-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA219884%22&limit=1) (`fda-drugs-nda219884-2025-12-11-4f2f3a1ba50d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA219884." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#fda-drugs-nda219884-v1 SHA-256: 909dc27392fa1c65e6f2e1e2aa32c29afc65adc0117b6d5c68f1f79eab6c8a22.

---

<a id="federal-register-2023-06593-v1"></a>

## Federal Register notice 2023-06593

> The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.

- Evidence object: `story:federal-register-2023-06593:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-06593/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2023-06593-v1
- Content SHA-256: `31a677c29f307bd2f5416fd5f58922a454b28436a058a7341e6085b690ccdeef`

### Claims and source pins

#### Headline

Federal Register notice 2023-06593 ([`federal-register-2023-06593-5a9a25299322`](#source-federal-register-2023-06593-5a9a25299322))

#### Summary

The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide. ([`federal-register-2023-06593-5a9a25299322`](#source-federal-register-2023-06593-5a9a25299322))

#### Paragraph 1

The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide. ([`federal-register-2023-06593-5a9a25299322`](#source-federal-register-2023-06593-5a9a25299322))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-06593-5a9a25299322`](#source-federal-register-2023-06593-5a9a25299322))

### Sources

<a id="source-federal-register-2023-06593-5a9a25299322"></a>
- **Federal Register notice 2023-06593 · published 2023-03-30 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06593.pdf) (`federal-register-2023-06593-5a9a25299322`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-06593." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2023-06593-v1 SHA-256: 31a677c29f307bd2f5416fd5f58922a454b28436a058a7341e6085b690ccdeef.

---

<a id="federal-register-2024-21941-v1"></a>

## Federal Register notice 2024-21941

> The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.

- Evidence object: `story:federal-register-2024-21941:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-21941/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2024-21941-v1
- Content SHA-256: `4a1f2eb672a9a00f6f9e7afb8f83c90f810239a2abaa079f3e71213c828111d7`

### Claims and source pins

#### Headline

Federal Register notice 2024-21941 ([`federal-register-2024-21941-a4d0a30f86f0`](#source-federal-register-2024-21941-a4d0a30f86f0))

#### Summary

The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide. ([`federal-register-2024-21941-a4d0a30f86f0`](#source-federal-register-2024-21941-a4d0a30f86f0))

#### Paragraph 1

The Federal Register published notice 2024-21941, attributed to FDA and its parent HHS department, on 2024-09-25. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide. ([`federal-register-2024-21941-a4d0a30f86f0`](#source-federal-register-2024-21941-a4d0a30f86f0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-21941-a4d0a30f86f0`](#source-federal-register-2024-21941-a4d0a30f86f0))

### Sources

<a id="source-federal-register-2024-21941-a4d0a30f86f0"></a>
- **Federal Register notice 2024-21941 · published 2024-09-25 · Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21941.pdf) (`federal-register-2024-21941-a4d0a30f86f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-21941." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#federal-register-2024-21941-v1 SHA-256: 4a1f2eb672a9a00f6f9e7afb8f83c90f810239a2abaa079f3e71213c828111d7.

---

<a id="pubmed-pmid-37279541-trofinetide-v1"></a>

## Trofinetide.

> PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37279541-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-10-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37279541-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37279541-trofinetide-v1
- Content SHA-256: `bc51c9d4d5cba7516478ab49af8f7f94fd99dd3c1d4783061accfa457399e5ee`

### Claims and source pins

#### Headline

Trofinetide. ([`pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6`](#source-pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6))

#### Summary

PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6`](#source-pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6))

#### Paragraph 1

PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6`](#source-pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6`](#source-pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6))

### Sources

<a id="source-pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6"></a>
- **Trofinetide. · retained source version 1:2023-10-24:current:b6a89c9fbdd66fbaac6f144bad6de64b904f9dff1f9c4dde63f9c6b89adea4af** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37279541/) (`pubmed-observation-pmid-37279541-2023-10-24-b6a89c9fbdd6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37279541-trofinetide-v1 SHA-256: bc51c9d4d5cba7516478ab49af8f7f94fd99dd3c1d4783061accfa457399e5ee.

---

<a id="pubmed-pmid-37291210-trofinetide-v1"></a>

## Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

> PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37291210-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37291210-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37291210-trofinetide-v1
- Content SHA-256: `0e19eab293b315007e850c0ef29bf1b3fbec474d79f51459328e2d33ddd7d48f`

### Claims and source pins

#### Headline

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. ([`pubmed-observation-pmid-37291210-2025-12-01-1e6945877def`](#source-pubmed-observation-pmid-37291210-2025-12-01-1e6945877def))

#### Summary

PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37291210-2025-12-01-1e6945877def`](#source-pubmed-observation-pmid-37291210-2025-12-01-1e6945877def))

#### Paragraph 1

PubMed lists PMID 37291210 in Nature medicine as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37291210-2025-12-01-1e6945877def`](#source-pubmed-observation-pmid-37291210-2025-12-01-1e6945877def))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37291210-2025-12-01-1e6945877def`](#source-pubmed-observation-pmid-37291210-2025-12-01-1e6945877def))

### Sources

<a id="source-pubmed-observation-pmid-37291210-2025-12-01-1e6945877def"></a>
- **Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. · retained source version 1:2025-12-01:current:1e6945877def3b5d9b1b1c0b6a13daad9cb9b545e88cbe3f9b62652234937d62** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37291210/) (`pubmed-observation-pmid-37291210-2025-12-01-1e6945877def`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37291210-trofinetide-v1 SHA-256: 0e19eab293b315007e850c0ef29bf1b3fbec474d79f51459328e2d33ddd7d48f.

---

<a id="pubmed-pmid-37460385-trofinetide-v1"></a>

## Trofinetide: a pioneering treatment for Rett syndrome.

> PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37460385-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37460385-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37460385-trofinetide-v1
- Content SHA-256: `8bb76ad9f2bee2636d186583877ef1b637b7bea2594590b1c2bfc4488d94fa7a`

### Claims and source pins

#### Headline

Trofinetide: a pioneering treatment for Rett syndrome. ([`pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b`](#source-pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b))

#### Summary

PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b`](#source-pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b))

#### Paragraph 1

PubMed lists PMID 37460385 in Trends in pharmacological sciences as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b`](#source-pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b`](#source-pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b))

### Sources

<a id="source-pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b"></a>
- **Trofinetide: a pioneering treatment for Rett syndrome. · retained source version 1:2024-10-03:current:1fbe8c7a869b6669d32e22ccf5af1fc270c4cc578c503ef733dd193dff388802** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37460385/) (`pubmed-observation-pmid-37460385-2024-10-03-1fbe8c7a869b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide: a pioneering treatment for Rett syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-37460385-trofinetide-v1 SHA-256: 8bb76ad9f2bee2636d186583877ef1b637b7bea2594590b1c2bfc4488d94fa7a.

---

<a id="pubmed-pmid-38035006-trofinetide-v1"></a>

## Trofinetide-a new chapter in rett syndrome's treatment.

> PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38035006-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38035006-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38035006-trofinetide-v1
- Content SHA-256: `f1d1797b4d7199e8d3e13cc897e03df67224fc80bb2726d718c562930a6232c9`

### Claims and source pins

#### Headline

Trofinetide-a new chapter in rett syndrome's treatment. ([`pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d`](#source-pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d))

#### Summary

PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d`](#source-pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d))

#### Paragraph 1

PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d`](#source-pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d`](#source-pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d))

### Sources

<a id="source-pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d"></a>
- **Trofinetide-a new chapter in rett syndrome's treatment. · retained source version 1:2023-12-02:current:a2366d99985d4039de7b1916f65f6e36c742dca533ba6503f6d1fe0a5d687c3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38035006/) (`pubmed-observation-pmid-38035006-2023-12-02-a2366d99985d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide-a new chapter in rett syndrome's treatment." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38035006-trofinetide-v1 SHA-256: f1d1797b4d7199e8d3e13cc897e03df67224fc80bb2726d718c562930a6232c9.

---

<a id="pubmed-pmid-38318312-trofinetide-v1"></a>

## Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.

> PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38318312-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38318312-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38318312-trofinetide-v1
- Content SHA-256: `41775d5e588d22429b8589fd86a128119f3c6801d2b463b81814ae76343e64fa`

### Claims and source pins

#### Headline

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. ([`pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d`](#source-pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d))

#### Summary

PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d`](#source-pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d))

#### Paragraph 1

PubMed lists PMID 38318312 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2024-01-22 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d`](#source-pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d`](#source-pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d))

### Sources

<a id="source-pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d"></a>
- **Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. · retained source version 1:2024-10-31:current:1cd0d41cdd0d0c511086c0a7d2c41b13ee59c2ee1fe622398a410205ec38dbec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38318312/) (`pubmed-observation-pmid-38318312-2024-10-31-1cd0d41cdd0d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of trofinetide for the treatment of Rett syndrome: from bench to bedside." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38318312-trofinetide-v1 SHA-256: 41775d5e588d22429b8589fd86a128119f3c6801d2b463b81814ae76343e64fa.

---

<a id="pubmed-pmid-38378975-trofinetide-v1"></a>

## Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.

> PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38378975-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38378975-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38378975-trofinetide-v1
- Content SHA-256: `34c11ed1cec2c7aa7231784bc0dcdbf7321b84ebf21fafbab16a4ba34d6cb8a2`

### Claims and source pins

#### Headline

Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives. ([`pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8`](#source-pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8))

#### Summary

PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8`](#source-pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8))

#### Paragraph 1

PubMed lists PMID 38378975 in Advances in therapy as Clinical Trial, Phase III, Journal Article, with publication-date metadata of 2024-02-20 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8`](#source-pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8`](#source-pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8))

### Sources

<a id="source-pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8"></a>
- **Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives. · retained source version 1:2026-01-16:current:b7132ceeb4f824db8522bf023e91e93e95685165105fe95833c921d4f052961b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38378975/) (`pubmed-observation-pmid-38378975-2026-01-16-b7132ceeb4f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38378975-trofinetide-v1 SHA-256: 34c11ed1cec2c7aa7231784bc0dcdbf7321b84ebf21fafbab16a4ba34d6cb8a2.

---

<a id="pubmed-pmid-38555801-trofinetide-v1"></a>

## Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome.

> PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38555801-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38555801-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38555801-trofinetide-v1
- Content SHA-256: `1bcfaca1a1d8eb184916bde309eae216ddaa7644b565dc5dbc55c4bcae3086a9`

### Claims and source pins

#### Headline

Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome. ([`pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b`](#source-pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b))

#### Summary

PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b`](#source-pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b))

#### Paragraph 1

PubMed lists PMID 38555801 in Asian journal of psychiatry as Letter, with publication-date metadata of 2024-03-19 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b`](#source-pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b`](#source-pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b))

### Sources

<a id="source-pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b"></a>
- **Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome. · retained source version 1:2024-05-11:current:301b0cd6cf5b8ede0bd10b9835c293184176916272c546694a651d3ad79040ab** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38555801/) (`pubmed-observation-pmid-38555801-2024-05-11-301b0cd6cf5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38555801-trofinetide-v1 SHA-256: 1bcfaca1a1d8eb184916bde309eae216ddaa7644b565dc5dbc55c4bcae3086a9.

---

<a id="pubmed-pmid-38869952-trofinetide-v1"></a>

## Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome.

> PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38869952-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38869952-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38869952-trofinetide-v1
- Content SHA-256: `ce2abcbc7b5c19cf25ad3a163b0774b703b13b7d213e61ecec724561c28d42ad`

### Claims and source pins

#### Headline

Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome. ([`pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb`](#source-pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb))

#### Summary

PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb`](#source-pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb))

#### Paragraph 1

PubMed lists PMID 38869952 in Expert review of gastroenterology & hepatology as Journal Article, Review, with publication-date metadata of 2024-06-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb`](#source-pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb`](#source-pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb))

### Sources

<a id="source-pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb"></a>
- **Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome. · retained source version 1:2024-07-16:current:cee7b36fb0bb7148b9beb111edc08009a5f043439c354a784952ee52e0b4d5b8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38869952/) (`pubmed-observation-pmid-38869952-2024-07-16-cee7b36fb0bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38869952-trofinetide-v1 SHA-256: ce2abcbc7b5c19cf25ad3a163b0774b703b13b7d213e61ecec724561c28d42ad.

---

<a id="pubmed-pmid-38981105-trofinetide-v1"></a>

## Trofinetide (Daybue) for Rett syndrome.

> PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38981105-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38981105-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38981105-trofinetide-v1
- Content SHA-256: `f8f5b81fb1538cef789500a523811af4e35f1fea8bdf85970e3fd26b214895d2`

### Claims and source pins

#### Headline

Trofinetide (Daybue) for Rett syndrome. ([`pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8`](#source-pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8))

#### Summary

PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8`](#source-pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8))

#### Paragraph 1

PubMed lists PMID 38981105 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2024-07-08 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8`](#source-pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8`](#source-pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8))

### Sources

<a id="source-pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8"></a>
- **Trofinetide (Daybue) for Rett syndrome. · retained source version 1:2024-07-15:current:46a3d1c0c2e8d6ae19f1e0cc145ee7744994f9be9c706196b4db399a15d5a6b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38981105/) (`pubmed-observation-pmid-38981105-2024-07-15-46a3d1c0c2e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide (Daybue) for Rett syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-38981105-trofinetide-v1 SHA-256: f8f5b81fb1538cef789500a523811af4e35f1fea8bdf85970e3fd26b214895d2.

---

<a id="pubmed-pmid-39395401-trofinetide-v1"></a>

## Trofinetide treatment for Rett syndrome: Lessons to learn.

> PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39395401-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39395401-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39395401-trofinetide-v1
- Content SHA-256: `cf6026c0f2953bc5fab2d827596f6962128d31f1f21785873f50533f0a434615`

### Claims and source pins

#### Headline

Trofinetide treatment for Rett syndrome: Lessons to learn. ([`pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9`](#source-pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9))

#### Summary

PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9`](#source-pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9))

#### Paragraph 1

PubMed lists PMID 39395401 in Med (New York, N.Y.) as Journal Article, Comment, with publication-date metadata of 2024-10-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9`](#source-pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9`](#source-pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9))

### Sources

<a id="source-pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9"></a>
- **Trofinetide treatment for Rett syndrome: Lessons to learn. · retained source version 1:2026-06-04:current:803b92913ad9bc5c426197cded4a94d759a4ad8c00de01eed477354776164b93** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39395401/) (`pubmed-observation-pmid-39395401-2026-06-04-803b92913ad9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Trofinetide treatment for Rett syndrome: Lessons to learn." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39395401-trofinetide-v1 SHA-256: cf6026c0f2953bc5fab2d827596f6962128d31f1f21785873f50533f0a434615.

---

<a id="pubmed-pmid-39692837-trofinetide-v1"></a>

## Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.

> PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39692837-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39692837-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39692837-trofinetide-v1
- Content SHA-256: `f779825aa52d1da68bd9f85a00f3041603d84319cc9b8de014c5f95e51dd4dc8`

### Claims and source pins

#### Headline

Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome. ([`pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f`](#source-pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f))

#### Summary

PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f`](#source-pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f))

#### Paragraph 1

PubMed lists PMID 39692837 in Advances in therapy as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-12-18 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f`](#source-pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f`](#source-pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f))

### Sources

<a id="source-pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f"></a>
- **Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome. · retained source version 1:2026-08-17:current:396ace5b868f7f3724f4f2c5943205eea5dcd4908af111273cb21c140e0a1dd3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39692837/) (`pubmed-observation-pmid-39692837-2026-08-17-396ace5b868f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39692837-trofinetide-v1 SHA-256: f779825aa52d1da68bd9f85a00f3041603d84319cc9b8de014c5f95e51dd4dc8.

---

<a id="pubmed-pmid-39824747-trofinetide-v1"></a>

## Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials.

> PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39824747-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39824747-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39824747-trofinetide-v1
- Content SHA-256: `b238ce235071f5236b4ecb4e4e34ef9958ef1bdbefc946d98c5f62727f286868`

### Claims and source pins

#### Headline

Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials. ([`pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc`](#source-pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc))

#### Summary

PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc`](#source-pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc))

#### Paragraph 1

PubMed lists PMID 39824747 in Clinical therapeutics as Journal Article, with publication-date metadata of 2025-01-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc`](#source-pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc`](#source-pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc))

### Sources

<a id="source-pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc"></a>
- **Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials. · retained source version 1:2025-05-22:current:cc8b040fbeccad842cc682fce778d73eeaf82176deb3eb5898dc1132ac7c4ca8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39824747/) (`pubmed-observation-pmid-39824747-2025-05-22-cc8b040fbecc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-39824747-trofinetide-v1 SHA-256: b238ce235071f5236b4ecb4e4e34ef9958ef1bdbefc946d98c5f62727f286868.

---

<a id="pubmed-pmid-41850142-trofinetide-v1"></a>

## Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy.

> PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41850142-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41850142-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-41850142-trofinetide-v1
- Content SHA-256: `4392fd65e7cea10e537b8272ae34193a6321bd48442443089ad9abe898e7f9b8`

### Claims and source pins

#### Headline

Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. ([`pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c`](#source-pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c))

#### Summary

PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c`](#source-pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c))

#### Paragraph 1

PubMed lists PMID 41850142 in Bioorganic & medicinal chemistry as Journal Article, with publication-date metadata of 2026-03-14 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c`](#source-pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c`](#source-pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c))

### Sources

<a id="source-pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c"></a>
- **Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. · retained source version 1:2026-07-11:current:244df2acb68c91d9b81d5b2b8ca918a7e51c006a6a84b9da4b90d2f1d9743e76** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41850142/) (`pubmed-observation-pmid-41850142-2026-07-11-244df2acb68c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-41850142-trofinetide-v1 SHA-256: 4392fd65e7cea10e537b8272ae34193a6321bd48442443089ad9abe898e7f9b8.

---

<a id="pubmed-pmid-42083929-trofinetide-v1"></a>

## Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues.

> PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42083929-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42083929-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42083929-trofinetide-v1
- Content SHA-256: `ea6620c35aadb8722e0de5628baba5e92715c01646d50fadd001ed14e4d924f5`

### Claims and source pins

#### Headline

Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues. ([`pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca`](#source-pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca))

#### Summary

PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca`](#source-pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca))

#### Paragraph 1

PubMed lists PMID 42083929 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2026 (year precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca`](#source-pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca`](#source-pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca))

### Sources

<a id="source-pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca"></a>
- **Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues. · retained source version 1:2026-07-16:current:9105d1304fca542e3ee2043711fbee374ad7e1a2b2174df6d071482cebd10a8c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42083929/) (`pubmed-observation-pmid-42083929-2026-07-16-9105d1304fca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42083929-trofinetide-v1 SHA-256: ea6620c35aadb8722e0de5628baba5e92715c01646d50fadd001ed14e4d924f5.

---

<a id="pubmed-pmid-42287113-trofinetide-v1"></a>

## Rett syndrome and real-world treatment patterns of trofinetide in the United States.

> PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42287113-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42287113-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42287113-trofinetide-v1
- Content SHA-256: `64cf48a769e8c6853ca0c9b2f2f9e2bac9b3157ed2b2102a90a4377eccd87cb6`

### Claims and source pins

#### Headline

Rett syndrome and real-world treatment patterns of trofinetide in the United States. ([`pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09`](#source-pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09))

#### Summary

PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09`](#source-pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09))

#### Paragraph 1

PubMed lists PMID 42287113 in Journal of medical economics as Journal Article, with publication-date metadata of 2026-06-13 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09`](#source-pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09`](#source-pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09))

### Sources

<a id="source-pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09"></a>
- **Rett syndrome and real-world treatment patterns of trofinetide in the United States. · retained source version 1:2026-06-13:current:3e1fd975fc09cebfd514d7e54518476584fd4ce39bf183b2887c47b93cb2defd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42287113/) (`pubmed-observation-pmid-42287113-2026-06-13-3e1fd975fc09`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rett syndrome and real-world treatment patterns of trofinetide in the United States." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42287113-trofinetide-v1 SHA-256: 64cf48a769e8c6853ca0c9b2f2f9e2bac9b3157ed2b2102a90a4377eccd87cb6.

---

<a id="pubmed-pmid-42294489-trofinetide-v1"></a>

## Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States.

> PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42294489-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42294489-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42294489-trofinetide-v1
- Content SHA-256: `8f4f85b2dd09c5237a2e5538b2b0d94dee85796f1de08c0a5471cceea08c3465`

### Claims and source pins

#### Headline

Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States. ([`pubmed-observation-pmid-42294489-2026-09-26-2377f0792967`](#source-pubmed-observation-pmid-42294489-2026-09-26-2377f0792967))

#### Summary

PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42294489-2026-09-26-2377f0792967`](#source-pubmed-observation-pmid-42294489-2026-09-26-2377f0792967))

#### Paragraph 1

PubMed lists PMID 42294489 in Journal of health economics and outcomes research as Journal Article, with publication-date metadata of 2026-06-11 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42294489-2026-09-26-2377f0792967`](#source-pubmed-observation-pmid-42294489-2026-09-26-2377f0792967))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42294489-2026-09-26-2377f0792967`](#source-pubmed-observation-pmid-42294489-2026-09-26-2377f0792967))

### Sources

<a id="source-pubmed-observation-pmid-42294489-2026-09-26-2377f0792967"></a>
- **Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States. · retained source version 1:2026-09-26:current:2377f0792967d0b3e7d4a325ae00a1a72c704fd9628695cf1729a7a2d29c3b8a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42294489/) (`pubmed-observation-pmid-42294489-2026-09-26-2377f0792967`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42294489-trofinetide-v1 SHA-256: 8f4f85b2dd09c5237a2e5538b2b0d94dee85796f1de08c0a5471cceea08c3465.

---

<a id="pubmed-pmid-42377739-trofinetide-v1"></a>

## Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide.

> PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42377739-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42377739-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42377739-trofinetide-v1
- Content SHA-256: `c2bb095566ca4ac58c19dec50ca49bf4fda17baf622fa8ed53eb25777992f168`

### Claims and source pins

#### Headline

Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide. ([`pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8`](#source-pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8))

#### Summary

PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8`](#source-pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8))

#### Paragraph 1

PubMed lists PMID 42377739 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8`](#source-pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8`](#source-pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8))

### Sources

<a id="source-pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8"></a>
- **Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide. · retained source version 1:2026-10-01:current:f347d406e0c82aa7df48455f585f12b1ea9a1ea2be56e637fe93892c101d74ad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42377739/) (`pubmed-observation-pmid-42377739-2026-10-01-f347d406e0c8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42377739-trofinetide-v1 SHA-256: c2bb095566ca4ac58c19dec50ca49bf4fda17baf622fa8ed53eb25777992f168.

---

<a id="pubmed-pmid-42530159-trofinetide-v1"></a>

## Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis.

> PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42530159-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42530159-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42530159-trofinetide-v1
- Content SHA-256: `81d47cb02b91fd23c95433e94bb84cbda5b729c5827cf67afae17aa75685d3b9`

### Claims and source pins

#### Headline

Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. ([`pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050`](#source-pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050))

#### Summary

PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050`](#source-pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050))

#### Paragraph 1

PubMed lists PMID 42530159 in Journal of computational chemistry as Journal Article, with publication-date metadata of 2026-08-05 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050`](#source-pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050`](#source-pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050))

### Sources

<a id="source-pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050"></a>
- **Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. · retained source version 1:2026-08-13:current:567c9f9ae050e9c047e4883452890a26bf46124687c391a4570081a120925d54** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42530159/) (`pubmed-observation-pmid-42530159-2026-08-13-567c9f9ae050`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42530159-trofinetide-v1 SHA-256: 81d47cb02b91fd23c95433e94bb84cbda5b729c5827cf67afae17aa75685d3b9.

---

<a id="pubmed-pmid-42563928-trofinetide-v1"></a>

## Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method.

> PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42563928-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42563928-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42563928-trofinetide-v1
- Content SHA-256: `bbb522545ff6ccb4d3a9d70011d4d668fb27c643e7fa34b8dd4dd13bb8a737bd`

### Claims and source pins

#### Headline

Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. ([`pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2`](#source-pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2))

#### Summary

PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2`](#source-pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2))

#### Paragraph 1

PubMed lists PMID 42563928 in Annals of the Child Neurology Society as Journal Article, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2`](#source-pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2`](#source-pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2))

### Sources

<a id="source-pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2"></a>
- **Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. · retained source version 1:2026-08-13:current:18d90e7808b23db224cba424569b72b48ed5468ba9e0ca41b2279bf59667e6c6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42563928/) (`pubmed-observation-pmid-42563928-2026-08-13-18d90e7808b2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42563928-trofinetide-v1 SHA-256: bbb522545ff6ccb4d3a9d70011d4d668fb27c643e7fa34b8dd4dd13bb8a737bd.

---

<a id="pubmed-pmid-42577214-trofinetide-v1"></a>

## Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States.

> PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42577214-trofinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42577214-trofinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42577214-trofinetide-v1
- Content SHA-256: `d3f805b1368fdf8e177f32dad3e152fd49c177614f96db092734045368f4d274`

### Claims and source pins

#### Headline

Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States. ([`pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403`](#source-pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403))

#### Summary

PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403`](#source-pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403))

#### Paragraph 1

PubMed lists PMID 42577214 in Frontiers in neurology as Journal Article, with publication-date metadata of 2026-07-27 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403`](#source-pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403`](#source-pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403))

### Sources

<a id="source-pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403"></a>
- **Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States. · retained source version 1:2026-08-28:current:b6c0596b44034a5adf82bc0fcfda58b5fc82f8ae6fdba6cf121cf5253fccca21** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42577214/) (`pubmed-observation-pmid-42577214-2026-08-28-b6c0596b4403`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/trofinetide.json#pubmed-pmid-42577214-trofinetide-v1 SHA-256: d3f805b1368fdf8e177f32dad3e152fd49c177614f96db092734045368f4d274.

